Orthotopic mouse models play a pivotal role in cancer research and drug development. These models entail the implantation of tumor cells into a mouse's organ of origin, closely mirroring the natural tumor environment, thus providing better clinical predictivity than subcutaneous approaches. Orthotopic models faithfully replicate the primary tumor site, enabling more precise examination of tumor growth, interactions with stromal cells and immune elements, and disease progression, including metastasis.
LIDE has established over several luciferace-labeled models for use in your preclinical studies. We could also establish new orthotopic models complimentary if you can't find them elsewhere.
Cell Line / CDX |
Source |
Labeled |
Model Availability |
GL261 |
Murine glioblastoma cancer |
N/A |
Yes |
U87-MG |
Human glioblastoma cancer |
Yes |
Yes |
HCT-116 |
Human colon cancer |
Yes |
Yes |
Hep3B |
Human liver cancer |
Yes |
Yes |
HepG2 |
Human liver cancer |
Yes |
In Progress |
A549 |
Human lung cancer |
Yes |
In Progress |
K562 |
Human chronic myelogenous leukemia |
Yes |
In Plan |
NALM-6 |
Human acute lymphoblastic leukemia |
Yes |
In Plan |
Raji |
Human Burkitts lymphoma |
Yes |
In Plan |
Orthotopic models offer a highly relevant tumor microenvironment (TME) akin to the human disease scenario. This makes them exceptionally valuable for investigating disease mechanisms, testing novel therapeutics designed for the metastatic niche, and generating responses to anticancer agents that closely parallel clinical outcomes. They deliver superior preclinical predictability compared to subcutaneous alternatives and are an indispensable resource for advancing our knowledge of cancer and developing effective treatments. Explore the potential of orthotopic mouse models for comprehensive cancer research and therapeutic development.